Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Celyad SA    CYAD   BE0974260896

CELYAD SA

(CYAD)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
04/12/2019 04/15/2019 04/16/2019 04/17/2019 04/18/2019 Date
19.1(c) 19.38(c) 19.02(c) 18.7(c) 18.28(c) Last
12 830 24 063 19 667 34 373 31 956 Volume
-0.10% +1.47% -1.86% -1.68% -2.25% Change
More quotes
Financials (EUR)
Sales 2019 5,58 M
EBIT 2019 -35,9 M
Net income 2019 -32,1 M
Finance 2019 15,6 M
Yield 2019 -
Sales 2020 65,1 M
EBIT 2020 17,6 M
Net income 2020 28,8 M
Finance 2020 125 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 36,3x
EV / Sales2020 1,44x
Capitalization 218 M
More Financials
Company
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad's CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its... 
More about the company
Surperformance© ratings of Celyad SA
Trading Rating : Investor Rating :
More Ratings
Latest news on CELYAD SA
04:57aCELYAD : to Present Update on allogeneic and autologous NKG2D-based CAR-T Candid..
AQ
04/18CELYAD : to Present Update on allogeneic and autologous NKG2D-based CAR-T Candid..
AQ
04/18CELYAD : - Celyad : to Present Update on allogeneic and autologous NKG2D-based C..
AQ
03/29CELYAD : - Celyad : Reports Business Update and Full Year 2018 Financial and Ope..
AQ
03/29CELYAD : - Celyad : Appoints Filippo Petti as Chief Executive Officer
AQ
03/28CELYAD : Appoints Filippo Petti as Chief Executive Officer
AQ
03/19CELYAD : - Celyad :'s 2019 R&D Day Highlights shRNA Platform and Pipeline of Nex..
AQ
03/08CELYAD : - Celyad : Appoints Anne Moore as Vice President Corporate Strategy
AQ
02/22CELYAD : - Celyad : Announces February and March 2019 Investor Conference Schedu..
AQ
02/22CELYAD : - Celyad : Outlines Key 2019 Priorities Including the Acceleration of t..
AQ
More news
Analyst Recommendations on CELYAD SA
More recommendations
Sector news : Biotechnology & Medical Research - NEC
04/16GILEAD SCIENCES : Insitro to Collaborate on Nonalcoholic Steatohepatitis
DJ
04/15PATRICK THOMAS : Novartis Files Application for Macular Degeneration Treatment
DJ
04/12GILEAD SCIENCES : Novo Nordisk Plan NASH Collaboration
DJ
04/08GSK wins U.S. nod for two-drug HIV combination
RE
04/08Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart CELYAD SA
Duration : Period :
Celyad SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELYAD SA
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 34,6 €
Spread / Average Target 89%
EPS Revisions
Managers
NameTitle
Christian Homsy Chief Executive Officer & Executive Director
Michel E. Lussier Chairman
Jean-Pierre Latere Chief Operating Officer
Filippo Joseph Petti Chief Financial Officer
Frederic Lehmann VP-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELYAD SA10.19%245
IQVIA HOLDINGS INC14.50%26 285
CELLTRION, INC.--.--%22 914
LONZA GROUP16.76%21 810
INCYTE CORPORATION16.31%15 847
EXACT SCIENCES CORPORATION46.13%11 596